Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry
Background Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited. Methods Adult patients with AD in the CorEvitas AD registry (2020–2021) who received systemic therapies for 4–12 months prior to enrollment were included based on disease severity: body surface...
Main Authors: | Jonathan I. Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A. Jones, Swapna S. Dave, Eric L. Simpson |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2023.2246601 |
Similar Items
-
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, et al.
Published: (2023-07-01) -
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
by: Jonathan I. Silverberg, MD, PhD, MPH, et al.
Published: (2024-06-01) -
Burden of adult atopic dermatitis and unmet needs with existing therapies
by: Elizabeth D. Bacci, et al.
Published: (2023-12-01) -
Update on Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2019-09-01) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01)